BTI
NVCR icon

Blue Trust Inc’s NovoCure NVCR Stock Holding History

Blue Trust Inc’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-28
Closed -$498 – 2648
2025
Q2 		$498 Sell
28
-4
-13% -$70 ﹤0.01% 2323
2025
Q1 		$570 Buy
+32
New +$727 ﹤0.01% 2351
2024
Q4 		– Sell
-1,105
Closed -$18.9K – 2798
2024
Q3 		$18.9K Buy
1,105
+676
+158% +$12.3K ﹤0.01% 1964
2024
Q2 		$6.71K Buy
429
+381
+794% +$6.7K ﹤0.01% 2085
2024
Q1 		$750 Hold
48
– – ﹤0.01% 1975
2023
Q4 		$1K Sell
48
-158
-77% -$2.12K ﹤0.01% 2371
2023
Q3 		$9K Buy
206
+18
+10% +$519 ﹤0.01% 1441
2023
Q2 		$11K Sell
188
-7
-4% -$435 ﹤0.01% 1281
2023
Q1 		$14K Buy
195
+7
+4% +$559 ﹤0.01% 1504
2022
Q4 		$14K Buy
188
+70
+59% +$5.27K ﹤0.01% 1423
2022
Q3 		$8K Hold
118
– – ﹤0.01% 1426
2022
Q2 		$10K Buy
+118
New +$8.89K ﹤0.01% 1209

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
QCM
Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Blue Trust Inc's NVCR Position: Q3 2025 in Review

Blue Trust Inc sold out of NovoCure (NVCR) in Q3 2025, closing a stake of 28 shares — an estimated $498 sold.

Blue Trust Inc first reported a position in NVCR in Q2 2022 and held it in 12 quarters. The position peaked at $18.9K in Q3 2024. 244 funds tracked by Wall St. Rank hold NVCR as of Q3 2025.

  • Blue Trust Inc reported no remaining NovoCure position as of Q3 2025 after selling out during the quarter.
  • Blue Trust Inc sold 28 NovoCure shares in Q3 2025, an estimated $498.
  • Blue Trust Inc first reported a position in NovoCure in Q2 2022 and held it in 12 quarters.
  • Blue Trust Inc's NovoCure position peaked at $18.9K in Q3 2024.
  • 244 funds tracked by Wall St. Rank held NovoCure as of Q3 2025.

Based on Blue Trust Inc's 13F filing for Q3 2025, filed 16 Oct 2025.